Login / Signup

Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States.

Christina L DeanJay W HooperJohn M DyeSamantha E ZakScott A KoepsellLaurence M CorashRichard J BenjaminSteve KwilasShannon BondsAnne M WinklerColleen S Kraft
Published in: Transfusion (2020)
Treatment of ECP with PRT to reduce the risk of TTI did not significantly reduce EBOV IgG antibody titers or neutralizing activity. Although ECP was used in the treatment of repatriated patients, no PRT units from this study were transfused to EVD patients. This inventory of PRT-treated ECP is currently available for future clinical evaluation.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • immune response
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • clinical evaluation
  • patient reported outcomes